Figure 2

Silencing of HMGN5 and TEX11 attenuates the proliferation of cisplatin-resistant TGCT-PDC and NEC8 cells in the presence of cisplatin. (a, b) Effects of control siRNA (siControl), HMGN5-specific siRNAs (siHMGN5 #1 and #2), or TEX11-specific siRNAs (siTEX11 #1 and #2) on the viability of parental TGCT-PDC (a) and cisplatin-resistant TGCT-PDC-R (b) cells analyzed by quantitation of intracellular ATP content in the absence of cisplatin. Results are shown as mean ± SE (n = 4). (c, d) HMGN5- and TEX11-specific siRNAs repress the viability of TGCT-PDC-R cells (d) but not of TGCT-PDC cells (c) treated with cisplatin (0.2 μM). (e, f) Effects of indicated siRNAs on the viability of parental NEC8 (e) and cisplatin-resistant NEC8-R (f) cells analyzed by WST-8 cell proliferation assay in the absence of cisplatin. (g, h) HMGN5- and TEX11-specific siRNAs repress the viability of NEC8-R cells (g) but not of NEC8 cells (h) treated with cisplatin (0.2 μM). *, P < 0.05; **, P < 0.01.